RediCare

RediCare to present its clinical data at the European Congress of Internal Medicine (ECIM 2022)

We are delighted to announce our recent clinical outcomes from primary care have been accepted by European Congress of Internal Medicine (ECIM 2022) to be presented at the congress in Malaga, Spain on the 9-11 June, 2022.

The title of the presentation will be:

DIGITAL LIFESTYLE CHANGE POSITIVELY IMPACTS METABOLIC SYNDROME PARAMETERS IN TYPE II DIABETES 

This is RediCare’s second time to present its clinical data at the European Congress of Internal Medicine.  We are delighted to be back presenting our latest clinical data at the ECIM. Presenting our latest clinical data at such a prestigious medical meeting speaks to the hard work of the RediCare team and the advancement of our product which is now been used to treat insulin dependent type 2 diabetic patients, commented Dr Niall Cowell, Consultant Cardiologist and clinical advisor to RediCare.

This data shows the clinical effectiveness of a Digital Therapeutics delivering validated Lifestyle Therapy in a primary care setting in conjunction with a multi-disciplined team.

 About RediCare

RediCare is a Digital Therapeutics firm founded in 2015. RediCare’s core product RediCare Control uses software to treat Chronic conditions such as High Blood Pressure, Pre-Diabetes, Type 2 Diabetes, High Cholesterol, Polycystic Ovary Syndrome (PCOS), Obesity and Overweight conditions.

RediCare ControlDTx is creating a new normal in prescription digital therapeutics for treating these conditions. We envision a new way to treat diseases like Type 2 diabetes and heart disease by targeting the root cause, not just the effects, using prescription digital therapeutics to deliver personalized clinically validated lifestyle therapy.

RediCare partners with primary care practices in the UK and Ireland and serves over 140 corporate clients with chronic disease screening and management services.

See www.controldtx.com for further information on RediCare Control.

About ECIM

Following a history of successful meetings, the 20th European Congress of Internal Medicine will offer a great opportunity to acquire expert knowledge, learn and share successful experiences, discuss the latest breakthrough in clinical areas related to internal medicine, expand your network and benefit from meeting colleagues from around the world. This conference is tailored for internists and general internal medicine specialists. ECIM 2022 will bring together physicians, young researchers and leaders in the field, and provide them with a lively platform to learn and share their knowledge and views.

ECIM 2022 will once again focus on sharing innovative developments and providing a comprehensive overview of state-of-the art treatment of common conditions in internal medicine practice. The slogan of ECIM 2022, “Internal Medicine in the Front Line of Health Care”, highlights the leading role that internal medicine plays in providing health care to communities, particularly in the current environment. The current COVID-19 pandemic has confirmed the Internal Medicine must be one of the cornerstones of the European health care systems. Our holistic person-centered approach has been crucial to understand this new complex and multisystemic disease, to provide a comprehensive care to patients and to assure an efficient use of the resources.

We are excited to bring together physicians, young researchers, and leaders in the field, and provide a lively platform to learn and share their knowledge and views in a creative and engaging setting at the beautiful city of Malaga. The three-day programme built around excellent scientific abstract presentations, educational sessions and cutting-edge lectures given by experts in internal medicine will guarantee a memorable congress

See https://efim.org/ecim2022/  for further information on ECIM

About RediCare

RediCare is a digital therapeutics firm. With our core product RediCare ControlDTx patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in Weight, HbA1c, Blood Pressure and improved Lipid profiles and PCOS remission. Many Type 2 Diabetic patients have reduced and eliminated their diabetes medications.

RediCare ControlDTx is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like Type 2 diabetes and heart disease by targeting the root cause, not just the effects, using prescription digital therapeutics to deliver personalized clinically validated lifestyle therapy.

RediCare partners with primary care practices in the UK and Ireland and serves over 140 corporate clients with chronic disease screening and management services.